Product Images Atorvastatin Calcium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Atorvastatin Calcium NDC 68071-2293 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PDP - 68071 2293 9

PDP - 68071 2293 9

NuCare Pharmaceuticals, Inc. is a company that produces Atorvastatin Calcium 40mg tablets. The lot number is 000000, the manufacturer's reference number (NDC) is 68071-2293-9, and the product number is R1522090. The tablets come in bottles of 90 tablets, and the expiration date for this bottle is 00-00. The tablets should be kept at a controlled temperature between 68-77°F and should be kept out of the reach of children. If there are any issues with the medication, it should be reported to the manufacturer at 1-800-FDA-1088.*

figure 1 - atorvastatinfig1

figure 1 - atorvastatinfig1

This appears to be a graph displaying the cumulative incidence of something, possibly a medical condition or disease, with two lines representing the effects of atorvastatin and a placebo. The horizontal axis appears to represent years, with increments of 5. The vertical axis shows percentages, with values ranging from 0 to 40. There is also a statistic shown indicating a hazard ratio of 0.64 and a p-value of 0.0005.*

figure 2 - atorvastatinfig2

figure 2 - atorvastatinfig2

The text displays a graph showing the Cumulative Hazard percentage for Placebo and Aorvastatin, with the time to the First Primary Endpoint Through Four (4) Years of Follow-up (Years) ranging from 0 to 5. The Aorvastatin group has a lower hazard ratio (HR) than Placebo, with a value of 0.63 (0.48-0.83) and p-value of 0.001.*

figure 3 - atorvastatinfig3

figure 3 - atorvastatinfig3

The text describes the percentage of subjects who experienced an event in a study comparing the effects of two doses of Atorvastatin (10 mg and 80 mg) on major cardiovascular endpoint. The results indicate that Atorvastatin 80 mg reduced the risk of events compared to Atorvastatin 10 mg, with a hazard ratio of 0.78 (confidence interval: 0.63-0.89) and a p-value of 0.0002. The graph shows the time to the first major cardiovascular endpoint measured in years.*

structure - atorvastatinstrc

structure - atorvastatinstrc

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.